TriangleNCT02722668 · STUDY IN CONTEXT
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
Read the full study record and all posted results →
Linked outcomes
Simple proportions will be used to estimate the probability of grade II-IV actue GVHD.
Percentage of patients with grade III-IV acute GVHD.
Transplant Related Mortality
Percentage of subjects with donor chimerism.
Percentage of subjects with donor chimerism.
Percentage of subjects with donor chimerism.
Reported safety
Quality of life and patient-reported measures
No linked quality-of-life measure is recorded for this setting and study.
Full draft applicability and source-link record
- trial
- release id
- clinical-indications-draft-1
- disease state id
- ds-prolymphocytic-leukemia
- nct id
- NCT02722668
- trial label
- UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
- applicability
- narrower
- applicability note
- Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- provenance class
- registry-condition-search
- discovery note
- Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
- outcome Count
- 6
- harms Count
- 2
- qol Count
- 0
- outcomes
- release id
- clinical-indications-draft-1
- disease state id
- ds-prolymphocytic-leukemia
- nct id
- NCT02722668
- outcome key
- om-0000
- source section id
- NCT02722668-om-0000
- source outcome index
- 0
- endpoint
- Probability of Acute Graft Versus Host Disease (GVHD)
- endpoint definition
- Simple proportions will be used to estimate the probability of grade II-IV actue GVHD.
- time origin
- Day 100
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-prolymphocytic-leukemia
- nct id
- NCT02722668
- outcome key
- om-0001
- source section id
- NCT02722668-om-0001
- source outcome index
- 1
- endpoint
- Incidence of Acute GVHD
- endpoint definition
- Percentage of patients with grade III-IV acute GVHD.
- time origin
- Day 100
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-prolymphocytic-leukemia
- nct id
- NCT02722668
- outcome key
- om-0002
- source section id
- NCT02722668-om-0002
- source outcome index
- 2
- endpoint
- Transplant Related Mortality
- endpoint definition
- Transplant Related Mortality
- time origin
- 6 months post transplant
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-prolymphocytic-leukemia
- nct id
- NCT02722668
- outcome key
- om-0003
- source section id
- NCT02722668-om-0003
- source outcome index
- 3
- endpoint
- Chimerism
- endpoint definition
- Percentage of subjects with donor chimerism.
- time origin
- Day 21
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-prolymphocytic-leukemia
- nct id
- NCT02722668
- outcome key
- om-0004
- source section id
- NCT02722668-om-0004
- source outcome index
- 4
- endpoint
- Chimerism
- endpoint definition
- Percentage of subjects with donor chimerism.
- time origin
- Day 100
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-prolymphocytic-leukemia
- nct id
- NCT02722668
- outcome key
- om-0005
- source section id
- NCT02722668-om-0005
- source outcome index
- 5
- endpoint
- Chimerism
- endpoint definition
- Percentage of subjects with donor chimerism.
- time origin
- Day 180
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- arms
- release id
- clinical-indications-draft-1
- disease state id
- ds-prolymphocytic-leukemia
- nct id
- NCT02722668
- outcome key
- om-0000
- arm key
- OG000
- arm label
- No Anti-thymocyte Globulin (ATG)
- regimen
- Hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycles of multi-agent chemotherapy within the 3 months previous to umbilical cord blood transplantation.
- analyzed count
- 5
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT02722668-om-0000#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-prolymphocytic-leukemia
- nct id
- NCT02722668
- outcome key
- om-0000
- arm key
- OG001
- arm label
- Anti-thymocyte Globulin (ATG)
- regimen
- Hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplantation, should receive Anti-thymocyte Globulin (ATG) as part of their conditioning regimen.
- analyzed count
- 10
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT02722668-om-0000#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-prolymphocytic-leukemia
- nct id
- NCT02722668
- outcome key
- om-0001
- arm key
- OG000
- arm label
- No Anti-thymocyte Globulin (ATG)
- regimen
- Hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycles of multi-agent chemotherapy within the 3 months previous to umbilical cord blood transplantation.
- analyzed count
- 5
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT02722668-om-0001#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-prolymphocytic-leukemia
- nct id
- NCT02722668
- outcome key
- om-0001
- arm key
- OG001
- arm label
- Anti-thymocyte Globulin (ATG)
- regimen
- Hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplantation, should receive Anti-thymocyte Globulin (ATG) as part of their conditioning regimen.
- analyzed count
- 10
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT02722668-om-0001#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-prolymphocytic-leukemia
- nct id
- NCT02722668
- outcome key
- om-0002
- arm key
- OG000
- arm label
- No Anti-thymocyte Globulin (ATG)
- regimen
- Hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycles of multi-agent chemotherapy within the 3 months previous to umbilical cord blood transplantation.
- analyzed count
- 5
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT02722668-om-0002#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-prolymphocytic-leukemia
- nct id
- NCT02722668
- outcome key
- om-0002
- arm key
- OG001
- arm label
- Anti-thymocyte Globulin (ATG)
- regimen
- Hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplantation, should receive Anti-thymocyte Globulin (ATG) as part of their conditioning regimen.
- analyzed count
- 10
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT02722668-om-0002#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-prolymphocytic-leukemia
- nct id
- NCT02722668
- outcome key
- om-0003
- arm key
- OG000
- arm label
- No Anti-thymocyte Globulin (ATG)
- regimen
- Hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycles of multi-agent chemotherapy within the 3 months previous to umbilical cord blood transplantation.
- analyzed count
- 5
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT02722668-om-0003#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-prolymphocytic-leukemia
- nct id
- NCT02722668
- outcome key
- om-0003
- arm key
- OG001
- arm label
- Anti-thymocyte Globulin (ATG)
- regimen
- Hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplantation, should receive Anti-thymocyte Globulin (ATG) as part of their conditioning regimen.
- analyzed count
- 10
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT02722668-om-0003#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-prolymphocytic-leukemia
- nct id
- NCT02722668
- outcome key
- om-0004
- arm key
- OG000
- arm label
- No Anti-thymocyte Globulin (ATG)
- regimen
- Hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycles of multi-agent chemotherapy within the 3 months previous to umbilical cord blood transplantation.
- analyzed count
- 5
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT02722668-om-0004#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-prolymphocytic-leukemia
- nct id
- NCT02722668
- outcome key
- om-0004
- arm key
- OG001
- arm label
- Anti-thymocyte Globulin (ATG)
- regimen
- Hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplantation, should receive Anti-thymocyte Globulin (ATG) as part of their conditioning regimen.
- analyzed count
- 8
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT02722668-om-0004#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-prolymphocytic-leukemia
- nct id
- NCT02722668
- outcome key
- om-0005
- arm key
- OG000
- arm label
- No Anti-thymocyte Globulin (ATG)
- regimen
- Hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycles of multi-agent chemotherapy within the 3 months previous to umbilical cord blood transplantation.
- analyzed count
- 4
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT02722668-om-0005#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-prolymphocytic-leukemia
- nct id
- NCT02722668
- outcome key
- om-0005
- arm key
- OG001
- arm label
- Anti-thymocyte Globulin (ATG)
- regimen
- Hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplantation, should receive Anti-thymocyte Globulin (ATG) as part of their conditioning regimen.
- analyzed count
- 8
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT02722668-om-0005#groups/OG001
- harms
- release id
- clinical-indications-draft-1
- disease state id
- ds-prolymphocytic-leukemia
- nct id
- NCT02722668
- harm key
- EG000
- source section id
- NCT02722668-ae
- event group key
- EG000
- event group label
- No Anti-thymocyte Globulin (ATG)
- serious affected
- 0
- serious at risk
- 5
- other affected
- 0
- other at risk
- 5
- frequency threshold
- 5
- collection period
- 6 months
- event definition
- Adverse event and/or serious adverse event recorded according to targeted reporting outlined in protocol. 1. Events requiring prompt reporting including, but not limited to unanticipated death of a locally enrolled subject(s); new or increased risk; any adverse event that require a change to the protocol or consent form or any protocol deviation that resulting in harm 2. graft failure by Day 42 post-transplant
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-prolymphocytic-leukemia
- nct id
- NCT02722668
- harm key
- EG001
- source section id
- NCT02722668-ae
- event group key
- EG001
- event group label
- Anti-thymocyte Globulin (ATG)
- serious affected
- 0
- serious at risk
- 10
- other affected
- 0
- other at risk
- 10
- frequency threshold
- 5
- collection period
- 6 months
- event definition
- Adverse event and/or serious adverse event recorded according to targeted reporting outlined in protocol. 1. Events requiring prompt reporting including, but not limited to unanticipated death of a locally enrolled subject(s); new or increased risk; any adverse event that require a change to the protocol or consent form or any protocol deviation that resulting in harm 2. graft failure by Day 42 post-transplant
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- quality of life
- setting source links
Preserved source evidence · Not medical advice